Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Hematology

Survivorship & Long-Term Monitoring

At a Glance

During AL amyloidosis survivorship, regular blood and urine tests are essential to monitor disease control and organ recovery. While harmful light chains can drop in weeks, organ healing takes 6 to 24 months, requiring strict daily fluid management and ongoing supportive care.

Moving into the survivorship phase of AL amyloidosis is a major milestone. After completing initial treatment, the focus shifts from “attacking the source” to “monitoring the response” and “supporting the organs” [1][2]. It is a time of vigilance, but also of healing.

The Surveillance Strategy

Monitoring in AL amyloidosis is done through regular blood and urine tests. These “surrogate markers” tell your team if the abnormal plasma cells are still suppressed and how your organs are recovering [3][4].

  • Hematologic Monitoring (The Source): Your sFLC (serum free light chains) are typically checked every 1 to 3 months [5][6]. This is the most sensitive way to detect if the disease is trying to return long before any symptoms appear [3].
  • Organ Monitoring (The Damage): Your heart and kidneys are monitored using NT-proBNP, Troponin, and 24-hour urine protein [7][8]. These markers are usually checked every 3 to 6 months once you are stable [9][8].

Hematologic vs. Organ Response

It is important to understand the “lag time” in AL amyloidosis recovery. In almost every case, the hematologic response (the drop in toxic light chains) happens much faster than the organ response (the healing of the heart or kidneys) [10][11].

  • Light chains can drop to safe levels within weeks of starting modern therapy [12][13].
  • Organ healing, however, is slow. It can take 6 to 24 months for the heart or kidneys to show measurable improvement on your lab tests [10][14]. Patience is a vital part of the survivorship journey.

Daily Life & Self-Care

Even after the light chains are under control, your organs may still have “scars” from the amyloid fibrils. If your heart or kidneys are involved, strict daily management is mandatory to prevent dangerous fluid overload [15].

  • Fluid and Salt Management: This involves eating a very low-sodium diet and adhering to potential fluid restrictions.
  • The Daily Scale: You must step on the scale every single morning. A sudden weight gain of 2-3 pounds overnight is not fat; it is fluid retention. You must report this to your doctor immediately.
  • Understanding “Dry Weight”: Your doctor will help you establish a “dry weight”—this is your true baseline weight when you do not have any excess fluid trapped in your body [15]. Diuretics (water pills) are often used to help you stay as close to this target as possible.

Managing Long-Term Supportive Care

Ongoing supportive care is often needed to manage chronic symptoms safely [1][2]:

  • Neurological Care: If you experience dizziness when standing (orthostatic hypotension), your doctor may prescribe medications like midodrine or droxidopa [16][17]. Non-medical support, such as abdominal binders or compression stockings, can also be very effective [18].
  • Renal Care: Protecting your kidneys means careful management of blood pressure and avoiding certain medications (like NSAIDs) that can further stress the renal system [19].

Addressing “Scanxiety” and Marker Anxiety

Waiting for test results—whether it’s an MRI or a simple blood draw—can trigger significant anxiety [20][21]. This “scanxiety” is a normal response to the uncertainty of a rare disease [20].

  • Mindfulness: Focusing on the present-moment can be more effective than ruminating on future “what-if” scenarios [22].
  • Clear Communication: Ask your clinic for a pre-set schedule for when and how results will be shared to minimize the “waiting in the dark” period [23][24].
  • Specialized Support: Connecting with a therapist or a support group for rare disease survivors can provide a safe space to process these unique emotional challenges [25][26].

Common questions in this guide

How often do I need blood tests during AL amyloidosis survivorship?
Serum free light chains (sFLC) are typically checked every 1 to 3 months to monitor the disease activity. Organ health markers, like NT-proBNP for the heart, are usually checked every 3 to 6 months once your condition is stable.
Why does it take so long for my organs to recover after treatment?
While modern treatments can lower abnormal light chain levels within weeks, organ healing is much slower. It can take 6 to 24 months for the heart or kidneys to show measurable improvement on your lab tests.
What is a 'dry weight' and why is tracking it important?
Your dry weight is your true baseline body weight when you do not have any excess fluid trapped in your tissues. Tracking this daily helps you and your doctor manage fluid buildup and adjust diuretics to protect your heart and kidneys.
How can I manage dizziness from AL amyloidosis?
Dizziness when standing, known as orthostatic hypotension, can be managed with medications like midodrine or droxidopa. Wearing compression stockings or abdominal binders can also provide excellent non-medical support.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific monitoring schedule for blood work and urine tests?
  2. 2.How long should I expect to wait for an organ response after my light chain levels have dropped?
  3. 3.Are my current heart symptoms caused by active disease or the long-term effects of previous amyloid damage?
  4. 4.What is my target 'dry weight' and how much variation is allowed before I need to call the clinic?
  5. 5.Can we schedule a follow-up call as soon as my lab results are available to reduce the waiting time?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.

    Muchtar E, Dispenzieri A, Gertz MA, et al.

    Mayo Clinic proceedings 2021; (96(6)):1546-1577 doi:10.1016/j.mayocp.2021.03.012.

    PMID: 34088417
  2. 2

    Supportive Care in AL Amyloidosis.

    Cibeira MT, Ortiz-Pérez JT, Quintana LF, et al.

    Acta haematologica 2020; (143(4)):335-342 doi:10.1159/000506760.

    PMID: 32235118
  3. 3

    Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.

    Mollee P, Merlini G

    Clinical chemistry and laboratory medicine 2016; (54(6)):921-7.

    PMID: 26812792
  4. 4

    Use of biomarkers to diagnose and manage cardiac amyloidosis.

    Castiglione V, Franzini M, Aimo A, et al.

    European journal of heart failure 2021; (23(2)):217-230 doi:10.1002/ejhf.2113.

    PMID: 33527656
  5. 5

    Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.

    Dejoie T, Attal M, Moreau P, et al.

    Haematologica 2016; (101(3)):356-62 doi:10.3324/haematol.2015.126797.

    PMID: 26635032
  6. 6

    Standardisation of minimal residual disease in multiple myeloma.

    Innao V, Allegra A, Russo S, et al.

    European journal of cancer care 2017; (26(6)) doi:10.1111/ecc.12732.

    PMID: 28671297
  7. 7

    Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis.

    Wees I, Hendren NS, Kaur G, et al.

    Current heart failure reports 2023; (20(5)):350-357 doi:10.1007/s11897-023-00616-y.

    PMID: 37428428
  8. 8

    Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.

    Muchtar E, Wisniowski B, Geyer S, et al.

    JAMA oncology 2024; (10(10)):1362-1369 doi:10.1001/jamaoncol.2024.2629.

    PMID: 39088206
  9. 9

    Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy.

    Benz DC, Clerc OF, Cuddy SAM, et al.

    JACC. Cardiovascular imaging 2025; (18(12)):1363-1374 doi:10.1016/j.jcmg.2025.07.017.

    PMID: 40938234
  10. 10

    Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.

    Martinez-Naharro A, Patel R, Kotecha T, et al.

    European heart journal 2022; (43(45)):4722-4735 doi:10.1093/eurheartj/ehac363.

    PMID: 36239754
  11. 11

    AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management.

    Tan M, Chen Y, Ooi M, et al.

    Annals of the Academy of Medicine, Singapore 2023; (52(11)):601-624 doi:10.47102/annals-acadmedsg.2023101.

    PMID: 38920149
  12. 12

    Organ responses with daratumumab therapy in previously treated AL amyloidosis.

    Chung A, Kaufman GP, Sidana S, et al.

    Blood advances 2020; (4(3)):458-466 doi:10.1182/bloodadvances.2019000776.

    PMID: 32027745
  13. 13

    Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era.

    Bazarbachi AH, Zanwar S, Hegenbart U, et al.

    HemaSphere 2025; (9(12)):e70276 doi:10.1002/hem3.70276.

    PMID: 41473002
  14. 14

    Cardiac Response Dynamics in Newly Diagnosed Light-Chain Amyloidosis Patients With Early and High-Quality Hematologic Response.

    Xu CY, Guan A, Zhang L, et al.

    JACC. Asia 2025; (5(1)):74-84 doi:10.1016/j.jacasi.2024.10.005.

    PMID: 39886192
  15. 15

    Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

    Hasib Sidiqi M, Gertz MA

    Blood cancer journal 2021; (11(5)):90 doi:10.1038/s41408-021-00483-7.

    PMID: 33993188
  16. 16

    Orthostatic Hypotension: A Practical Approach to Investigation and Management.

    Arnold AC, Raj SR

    The Canadian journal of cardiology 2017; (33(12)):1725-1728 doi:10.1016/j.cjca.2017.05.007.

    PMID: 28807522
  17. 17

    Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.

    Ho AH, Kinter CW, Wight J, et al.

    Journal of medical case reports 2020; (14(1)):73 doi:10.1186/s13256-020-02405-w.

    PMID: 32560740
  18. 18

    Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine.

    Okamoto LE, Diedrich A, Baudenbacher FJ, et al.

    Hypertension (Dallas, Tex. : 1979) 2016; (68(2)):418-26 doi:10.1161/HYPERTENSIONAHA.116.07199.

    PMID: 27271310
  19. 19

    Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis.

    Leung N, Comenzo R, Gillmore J, et al.

    Kidney international reports 2024; (9(7)):1986-1994 doi:10.1016/j.ekir.2024.03.033.

    PMID: 39081759
  20. 20

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  21. 21

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  22. 22

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  23. 23

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  24. 24

    "You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

    Derry-Vick H, Prigerson HG, Hahne J, et al.

    Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

    PMID: 41338711
  25. 25

    Surveillance-Associated Anxiety After Curative-Intent Cancer Surgery: A Systematic Review.

    Khatri R, Quinn PL, Wells-Di Gregorio S, et al.

    Annals of surgical oncology 2025; (32(1)):47-62 doi:10.1245/s10434-024-16287-5.

    PMID: 39343818
  26. 26

    Scanxiety: a scoping review about scan-associated anxiety.

    Bui KT, Liang R, Kiely BE, et al.

    BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

    PMID: 34039571

This page provides information on AL amyloidosis survivorship and long-term monitoring for educational purposes only. Always consult your hematologist or cardiologist regarding your specific care plan and test results.

Get notified when new evidence is published on AL amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.